JP2005517643A - ペルオキシソーム増殖因子活性化受容体アゴニスト - Google Patents
ペルオキシソーム増殖因子活性化受容体アゴニスト Download PDFInfo
- Publication number
- JP2005517643A JP2005517643A JP2003549322A JP2003549322A JP2005517643A JP 2005517643 A JP2005517643 A JP 2005517643A JP 2003549322 A JP2003549322 A JP 2003549322A JP 2003549322 A JP2003549322 A JP 2003549322A JP 2005517643 A JP2005517643 A JP 2005517643A
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxo
- propionic acid
- phenoxy
- imidazolidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 CC(C)OC(Cc(cc1)ccc1OCC[C@@](CN1Cc(cc2)ccc2C2=CC=C*(*)C=C2)N(C)C1=O)C(O)=O Chemical compound CC(C)OC(Cc(cc1)ccc1OCC[C@@](CN1Cc(cc2)ccc2C2=CC=C*(*)C=C2)N(C)C1=O)C(O)=O 0.000 description 17
- PICHCRNDTHKENF-UHFFFAOYSA-N CC(C)(C(C1CC1)O)OC1C=CC(OCCC(CN2Cc(cc3F)ccc3F)N(C)C2=O)=CC1 Chemical compound CC(C)(C(C1CC1)O)OC1C=CC(OCCC(CN2Cc(cc3F)ccc3F)N(C)C2=O)=CC1 PICHCRNDTHKENF-UHFFFAOYSA-N 0.000 description 1
- IOSQQCGETKQNHR-UHFFFAOYSA-N CC(C)(C(O)=O)Oc(cc1)ccc1OCCC(CN1Cc2ccc(C)c(C)c2)N(C)C1O Chemical compound CC(C)(C(O)=O)Oc(cc1)ccc1OCCC(CN1Cc2ccc(C)c(C)c2)N(C)C1O IOSQQCGETKQNHR-UHFFFAOYSA-N 0.000 description 1
- TVJNONVIMQZXBP-RUZDIDTESA-N CC(C)(C(O)=O)Oc(cc1)ccc1OCC[C@](C)(CN1Cc2ccc(C)cc2)N(C)C1=O Chemical compound CC(C)(C(O)=O)Oc(cc1)ccc1OCC[C@](C)(CN1Cc2ccc(C)cc2)N(C)C1=O TVJNONVIMQZXBP-RUZDIDTESA-N 0.000 description 1
- YPFHRFQHFDVKTR-UHFFFAOYSA-N CC(C)(C(O)=O)Oc1ccc(CCCC(N2)=CN(Cc3cc(F)cc(F)c3)C2=O)cc1 Chemical compound CC(C)(C(O)=O)Oc1ccc(CCCC(N2)=CN(Cc3cc(F)cc(F)c3)C2=O)cc1 YPFHRFQHFDVKTR-UHFFFAOYSA-N 0.000 description 1
- OWJBDECUOXIRSR-UHFFFAOYSA-N CC(C)(C)OC(C(C)(C)Oc1ccc(CCCC(C(N2)=O)NC2=O)cc1)=O Chemical compound CC(C)(C)OC(C(C)(C)Oc1ccc(CCCC(C(N2)=O)NC2=O)cc1)=O OWJBDECUOXIRSR-UHFFFAOYSA-N 0.000 description 1
- KQCHBFKCOOERHT-UHFFFAOYSA-N CC(C)(C)OC(C(C)(C)Oc1ccc(CCCC(C)=O)cc1)=O Chemical compound CC(C)(C)OC(C(C)(C)Oc1ccc(CCCC(C)=O)cc1)=O KQCHBFKCOOERHT-UHFFFAOYSA-N 0.000 description 1
- JKALENSADXOYCC-UHFFFAOYSA-N CC(C)(C)c1ccc(CN(C=C(CCCc(cc2)ccc2OCC(C)(C)C(O)=O)N2C)C2=O)cc1 Chemical compound CC(C)(C)c1ccc(CN(C=C(CCCc(cc2)ccc2OCC(C)(C)C(O)=O)N2C)C2=O)cc1 JKALENSADXOYCC-UHFFFAOYSA-N 0.000 description 1
- FEWCQZDNGWFLJF-MHZLTWQESA-N CC(C)(C)c1ccc(CN(C[C@H](CCCc(cc2CC=C)ccc2OC(C)(C)C(OC)=O)N2C)C2=O)cc1 Chemical compound CC(C)(C)c1ccc(CN(C[C@H](CCCc(cc2CC=C)ccc2OC(C)(C)C(OC)=O)N2C)C2=O)cc1 FEWCQZDNGWFLJF-MHZLTWQESA-N 0.000 description 1
- XORSRCBBBWWBKJ-UHFFFAOYSA-N CC(C)OC(Cc(cc1)ccc1N=O)C(OC)=O Chemical compound CC(C)OC(Cc(cc1)ccc1N=O)C(OC)=O XORSRCBBBWWBKJ-UHFFFAOYSA-N 0.000 description 1
- QXCBCCJFWSQUJK-XADRRFQNSA-N CC(C)OC(Cc(cc1)ccc1OCC[C@@H](CN1Cc(cc2)ccc2OC)N(C)C1=O)C(OC)=O Chemical compound CC(C)OC(Cc(cc1)ccc1OCC[C@@H](CN1Cc(cc2)ccc2OC)N(C)C1=O)C(OC)=O QXCBCCJFWSQUJK-XADRRFQNSA-N 0.000 description 1
- TZHOVRNKSPCVTD-RDJZCZTQSA-N CC(C)O[C@@H](Cc(cc1)ccc1OCC[C@@H](CN1)N(C)C1=O)C(OC)=O Chemical compound CC(C)O[C@@H](Cc(cc1)ccc1OCC[C@@H](CN1)N(C)C1=O)C(OC)=O TZHOVRNKSPCVTD-RDJZCZTQSA-N 0.000 description 1
- JAIUZSJWTSEZFL-UHFFFAOYSA-N CCCCC(CC)(C(O)=C=C)Oc1ccc(CCCC(CN2Cc3ccc(C(C)(C)C)cc3)N(C)C2O)cc1 Chemical compound CCCCC(CC)(C(O)=C=C)Oc1ccc(CCCC(CN2Cc3ccc(C(C)(C)C)cc3)N(C)C2O)cc1 JAIUZSJWTSEZFL-UHFFFAOYSA-N 0.000 description 1
- RPBIGDJQZGKJAU-FIBWVYCGSA-N CCCCCCN(C[C@H](CCOc1ccc(C[C@@](C)(C(O)=C)Oc2ccccc2)cc1)N1C)C1=C Chemical compound CCCCCCN(C[C@H](CCOc1ccc(C[C@@](C)(C(O)=C)Oc2ccccc2)cc1)N1C)C1=C RPBIGDJQZGKJAU-FIBWVYCGSA-N 0.000 description 1
- ZSXCFNOPEXSODZ-UHFFFAOYSA-N CCCN(C(C)(CCCc(cc1)ccc1OC(C)(C)C(O)=O)C(N1Cc2cc(F)cc(F)c2)=O)C1=O Chemical compound CCCN(C(C)(CCCc(cc1)ccc1OC(C)(C)C(O)=O)C(N1Cc2cc(F)cc(F)c2)=O)C1=O ZSXCFNOPEXSODZ-UHFFFAOYSA-N 0.000 description 1
- AHJPMTKGEKGCTA-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1O)=CN1Cc2cc(C(F)(F)F)cc(C(F)(F)I)c2)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1O)=CN1Cc2cc(C(F)(F)F)cc(C(F)(F)I)c2)C1=O AHJPMTKGEKGCTA-UHFFFAOYSA-N 0.000 description 1
- DOYQJJUAAZRBSQ-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1O)=CN1Cc2cc(F)cc(F)c2)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1O)=CN1Cc2cc(F)cc(F)c2)C1=O DOYQJJUAAZRBSQ-UHFFFAOYSA-N 0.000 description 1
- BDNHKLMIUXCUPO-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1O)=CN1Cc2ccc(C(C)C)cc2)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1O)=CN1Cc2ccc(C(C)C)cc2)C1=O BDNHKLMIUXCUPO-UHFFFAOYSA-N 0.000 description 1
- VFSKDCJJEHOCSQ-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1O)=CN1Cc2ccccc2)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1O)=CN1Cc2ccccc2)C1=O VFSKDCJJEHOCSQ-UHFFFAOYSA-N 0.000 description 1
- LUXQZZKRXYGXCP-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(O)=O)=CN1Cc(cc2Cl)ccc2Cl)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(O)=O)=CN1Cc(cc2Cl)ccc2Cl)C1=O LUXQZZKRXYGXCP-UHFFFAOYSA-N 0.000 description 1
- CLBRBFITLIIYRP-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(O)=O)=CN1Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(O)=O)=CN1Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)C1=O CLBRBFITLIIYRP-UHFFFAOYSA-N 0.000 description 1
- MRWBPESZTZVZKZ-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(O)=O)=CN1Cc2cc(C)c(C)cc2)[IH]1=O Chemical compound CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(O)=O)=CN1Cc2cc(C)c(C)cc2)[IH]1=O MRWBPESZTZVZKZ-UHFFFAOYSA-N 0.000 description 1
- OKDYHDXURKKVPE-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(O)=O)=CN1Cc2nc(cccc3)c3cc2)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(O)=O)=CN1Cc2nc(cccc3)c3cc2)C1=O OKDYHDXURKKVPE-UHFFFAOYSA-N 0.000 description 1
- YYGUPZRGLDXALJ-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(O)=[U])=CN1CCc2ccccc2)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(O)=[U])=CN1CCc2ccccc2)C1=O YYGUPZRGLDXALJ-UHFFFAOYSA-N 0.000 description 1
- JRIAZWMSHSADCT-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(OC(C)(C)C)=O)C(N1Cc2cc(C)c(C)cc2)=O)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(OC(C)(C)C)=O)C(N1Cc2cc(C)c(C)cc2)=O)C1=O JRIAZWMSHSADCT-UHFFFAOYSA-N 0.000 description 1
- UJFFVHJPELUQME-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(OCC)=O)=CN1Cc2ccc(C(C)C)cc2)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(OCC)=O)=CN1Cc2ccc(C(C)C)cc2)C1=O UJFFVHJPELUQME-UHFFFAOYSA-N 0.000 description 1
- DJLQQTSWQSJUCF-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(OCC)=O)=CN1Cc2ccc(C)c(C)c2)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1OC(C)(C)C(OCC)=O)=CN1Cc2ccc(C)c(C)c2)C1=O DJLQQTSWQSJUCF-UHFFFAOYSA-N 0.000 description 1
- CKNSMQBNMDVXKH-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1OC)=CN1Cc2ccc(C(C)(C)C)cc2)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1OC)=CN1Cc2ccc(C(C)(C)C)cc2)C1=O CKNSMQBNMDVXKH-UHFFFAOYSA-N 0.000 description 1
- HORQLQOFSVTQGZ-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1OC)C(N1Cc(cc2)ccc2F)=O)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1OC)C(N1Cc(cc2)ccc2F)=O)C1=O HORQLQOFSVTQGZ-UHFFFAOYSA-N 0.000 description 1
- KJWLXRFTCDHMBK-UHFFFAOYSA-N CCCN(C(CCCc(cc1)ccc1OC)C(N1Cc2cc3ccccc3cc2)=O)C1=O Chemical compound CCCN(C(CCCc(cc1)ccc1OC)C(N1Cc2cc3ccccc3cc2)=O)C1=O KJWLXRFTCDHMBK-UHFFFAOYSA-N 0.000 description 1
- BDEFGXBYAJYCOI-UHFFFAOYSA-N CCCN(C(CCOc(cc1)ccc1C(O)=O)CN1Cc2ccc(C)cc2)C1=O Chemical compound CCCN(C(CCOc(cc1)ccc1C(O)=O)CN1Cc2ccc(C)cc2)C1=O BDEFGXBYAJYCOI-UHFFFAOYSA-N 0.000 description 1
- ZRAUNHTWUGXGJC-UHFFFAOYSA-N CCCN(C=C(CCCc(cc1)ccc1O)N1Cc2cc(C)c(C)cc2)C1=O Chemical compound CCCN(C=C(CCCc(cc1)ccc1O)N1Cc2cc(C)c(C)cc2)C1=O ZRAUNHTWUGXGJC-UHFFFAOYSA-N 0.000 description 1
- VHQHSCSNQHGDKJ-UHFFFAOYSA-N CCCN(C=C(CCCc(cc1)ccc1OC)N1Cc2cc(C)c(C)cc2)C1=O Chemical compound CCCN(C=C(CCCc(cc1)ccc1OC)N1Cc2cc(C)c(C)cc2)C1=O VHQHSCSNQHGDKJ-UHFFFAOYSA-N 0.000 description 1
- FBYJFDJVBUOQTP-UHFFFAOYSA-N CCOC(C(C)(C)Oc(cc1)ccc1OCCC(CN1CC(C=C2)=CCC2OC)[I](C)C1O)=C Chemical compound CCOC(C(C)(C)Oc(cc1)ccc1OCCC(CN1CC(C=C2)=CCC2OC)[I](C)C1O)=C FBYJFDJVBUOQTP-UHFFFAOYSA-N 0.000 description 1
- WHVGFHDCQOLXJZ-UHFFFAOYSA-N CCOC(C(C)(C)Oc1ccc(CCCC(N2Cc3ccccc3)=CN(Cc3ccccc3)C2=O)cc1)=O Chemical compound CCOC(C(C)(C)Oc1ccc(CCCC(N2Cc3ccccc3)=CN(Cc3ccccc3)C2=O)cc1)=O WHVGFHDCQOLXJZ-UHFFFAOYSA-N 0.000 description 1
- YFMGJXKGGGPOTR-UHFFFAOYSA-N CCOC(C(C)(Cc(cc1)ccc1OCc1ccccc1)O)=O Chemical compound CCOC(C(C)(Cc(cc1)ccc1OCc1ccccc1)O)=O YFMGJXKGGGPOTR-UHFFFAOYSA-N 0.000 description 1
- LKZBYCFCKPZYLT-LKNOKMSNSA-N CCOC([C@](C)(Cc1ccc(/C=C/C[C@@H](CN2Cc3ccc(C(F)(F)F)cc3)N(C)C2=O)cc1)OC1=CC=CC=[I]1)=O Chemical compound CCOC([C@](C)(Cc1ccc(/C=C/C[C@@H](CN2Cc3ccc(C(F)(F)F)cc3)N(C)C2=O)cc1)OC1=CC=CC=[I]1)=O LKZBYCFCKPZYLT-LKNOKMSNSA-N 0.000 description 1
- MJAWWVLDYZKUEU-SANMLTNESA-N CCc1cc(CCC[C@@H](CN2Cc3ccc(C(C)(C)C)cc3)N(C)C2=O)ccc1OC(C)(C)C(OC)=O Chemical compound CCc1cc(CCC[C@@H](CN2Cc3ccc(C(C)(C)C)cc3)N(C)C2=O)ccc1OC(C)(C)C(OC)=O MJAWWVLDYZKUEU-SANMLTNESA-N 0.000 description 1
- PHHKYWZHLPEQEY-DEGOBNMZSA-N C[C@](Cc(cc1)ccc1OCCC(CN1Cc2cccc(Oc3ccccc3)c2)N(C)C1=O)(C(O)=O)Oc1ccccc1 Chemical compound C[C@](Cc(cc1)ccc1OCCC(CN1Cc2cccc(Oc3ccccc3)c2)N(C)C1=O)(C(O)=O)Oc1ccccc1 PHHKYWZHLPEQEY-DEGOBNMZSA-N 0.000 description 1
- ALHDOARENLXATD-RNAHPLFWSA-N C[C@](Cc(cc1)ccc1OCC[C@H](CN1Cc2ccc(C(F)(F)F)cc2)N(C)C1=O)(C(CO)=O)Oc1ccccc1 Chemical compound C[C@](Cc(cc1)ccc1OCC[C@H](CN1Cc2ccc(C(F)(F)F)cc2)N(C)C1=O)(C(CO)=O)Oc1ccccc1 ALHDOARENLXATD-RNAHPLFWSA-N 0.000 description 1
- KPVJDRVHUMYOQP-UHFFFAOYSA-N Cc(cc1)ccc1S(OCCC(CN1CC2C=CC(OC)=CC2)N(C)C1=O)=O Chemical compound Cc(cc1)ccc1S(OCCC(CN1CC2C=CC(OC)=CC2)N(C)C1=O)=O KPVJDRVHUMYOQP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/76—Two oxygen atoms, e.g. hydantoin with substituted hydrocarbon radicals attached to the third ring carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33445301P | 2001-11-30 | 2001-11-30 | |
| PCT/US2002/036128 WO2003048130A2 (en) | 2001-11-30 | 2002-11-26 | Peroxisome proliferator activated receptor agonists |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005517643A true JP2005517643A (ja) | 2005-06-16 |
| JP2005517643A5 JP2005517643A5 (enExample) | 2006-01-05 |
Family
ID=23307275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003549322A Pending JP2005517643A (ja) | 2001-11-30 | 2002-11-26 | ペルオキシソーム増殖因子活性化受容体アゴニスト |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7544812B2 (enExample) |
| EP (1) | EP1453811A2 (enExample) |
| JP (1) | JP2005517643A (enExample) |
| KR (1) | KR20050044606A (enExample) |
| CN (1) | CN1582279A (enExample) |
| AU (1) | AU2002356927A1 (enExample) |
| BR (1) | BR0214437A (enExample) |
| CA (1) | CA2468846A1 (enExample) |
| CO (1) | CO5640129A2 (enExample) |
| EA (1) | EA007163B1 (enExample) |
| HR (1) | HRP20040469A2 (enExample) |
| HU (1) | HUP0402486A3 (enExample) |
| IL (1) | IL161578A0 (enExample) |
| MX (1) | MXPA04005123A (enExample) |
| NO (1) | NO20042737L (enExample) |
| NZ (1) | NZ532909A (enExample) |
| PL (1) | PL370515A1 (enExample) |
| WO (1) | WO2003048130A2 (enExample) |
| ZA (1) | ZA200404173B (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009544675A (ja) * | 2006-07-24 | 2009-12-17 | ジェンフィ | 置換されたイミダゾロン誘導体、製造方法及び使用 |
| JP2024536448A (ja) * | 2022-01-20 | 2024-10-04 | 哈爾濱三聯薬業股▲フン▼有限公司 | ヒダントイン系化合物及びその医薬用途 |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1662487A (zh) | 2002-06-19 | 2005-08-31 | 伊莱利利公司 | 酰胺连接基过氧化物酶体增殖物激活受体调节剂 |
| US7816385B2 (en) * | 2002-12-20 | 2010-10-19 | High Point Pharmaceuticals, Llc | Dimeric dicarboxylic acid derivatives, their preparation and use |
| DE10351859A1 (de) * | 2003-11-06 | 2005-06-09 | Beiersdorf Ag | Emulsionen mit zwei Verdickungsmitteln |
| US20080125403A1 (en) | 2004-04-02 | 2008-05-29 | Merck & Co., Inc. | Method of Treating Men with Metabolic and Anthropometric Disorders |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| WO2006036512A2 (en) * | 2004-09-28 | 2006-04-06 | Allergan, Inc. | Unsubstituted and substituted 4-benzyl-1,3-dihydro-imidazole-2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same |
| CA2655574A1 (en) | 2006-06-20 | 2007-12-27 | Wyeth | Imidazole kv1.5 potassium channel inhibitors |
| WO2008094860A2 (en) | 2007-01-30 | 2008-08-07 | Allergan, Inc. | Treating ocular diseases using peroxisome proliferator-activated receptor delta antagonists |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
| ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
| CN101875636B (zh) * | 2010-05-18 | 2012-01-04 | 浙江大学 | 咪唑啉-2,4-二酮类衍生物及制备方法和用途 |
| WO2012027331A1 (en) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
| EP2968439A2 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| PL3004138T3 (pl) | 2013-06-05 | 2024-07-29 | Bausch Health Ireland Limited | Ultra-oczyszczeni agoniści peptydowi cyklazy guanylanowej C, sposób ich uzyskiwania i ich zastosowanie |
| CN114835655A (zh) * | 2022-04-14 | 2022-08-02 | 河南师范大学 | 一种合成光学活性三氟甲基丙烯酸酯类化合物的方法 |
| LU605402B1 (en) * | 2024-07-11 | 2026-07-14 | Sea4Us Biotecnologia E Recursos Marinhos Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3452041A (en) * | 1965-05-19 | 1969-06-24 | American Home Prod | Hydantoin compounds and methods of preparation |
| HU183046B (en) | 1976-06-03 | 1984-04-28 | Wellcome Found | Process for producing hydanthoine derivatives |
| GB1601310A (en) | 1978-05-23 | 1981-10-28 | Lilly Industries Ltd | Aryl hydantoins |
| JPS59159163A (ja) * | 1983-03-01 | 1984-09-08 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−感光材料 |
| GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
| PT966447E (pt) | 1997-03-03 | 2003-07-31 | Boehringer Ingelheim Pharma | Moleculas pequenas uteis no tratamento de doencas inflamatorias |
| WO2001016120A1 (en) * | 1999-08-27 | 2001-03-08 | Eli Lilly And Company | Biaryl-oxa(thia)zole derivatives and their use as ppars modulators |
-
2002
- 2002-11-26 HU HU0402486A patent/HUP0402486A3/hu unknown
- 2002-11-26 AU AU2002356927A patent/AU2002356927A1/en not_active Abandoned
- 2002-11-26 EA EA200400748A patent/EA007163B1/ru not_active IP Right Cessation
- 2002-11-26 PL PL02370515A patent/PL370515A1/xx not_active Application Discontinuation
- 2002-11-26 IL IL16157802A patent/IL161578A0/xx unknown
- 2002-11-26 JP JP2003549322A patent/JP2005517643A/ja active Pending
- 2002-11-26 HR HR20040469A patent/HRP20040469A2/hr not_active Application Discontinuation
- 2002-11-26 CA CA002468846A patent/CA2468846A1/en not_active Abandoned
- 2002-11-26 KR KR1020047008021A patent/KR20050044606A/ko not_active Withdrawn
- 2002-11-26 BR BR0214437-9A patent/BR0214437A/pt not_active IP Right Cessation
- 2002-11-26 NZ NZ532909A patent/NZ532909A/en unknown
- 2002-11-26 US US10/496,770 patent/US7544812B2/en not_active Expired - Fee Related
- 2002-11-26 WO PCT/US2002/036128 patent/WO2003048130A2/en not_active Ceased
- 2002-11-26 CN CNA028238001A patent/CN1582279A/zh active Pending
- 2002-11-26 MX MXPA04005123A patent/MXPA04005123A/es unknown
- 2002-11-26 EP EP02804416A patent/EP1453811A2/en not_active Withdrawn
-
2004
- 2004-05-27 ZA ZA200404173A patent/ZA200404173B/en unknown
- 2004-05-27 CO CO04049275A patent/CO5640129A2/es not_active Application Discontinuation
- 2004-06-29 NO NO20042737A patent/NO20042737L/no unknown
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009544675A (ja) * | 2006-07-24 | 2009-12-17 | ジェンフィ | 置換されたイミダゾロン誘導体、製造方法及び使用 |
| JP2024536448A (ja) * | 2022-01-20 | 2024-10-04 | 哈爾濱三聯薬業股▲フン▼有限公司 | ヒダントイン系化合物及びその医薬用途 |
| JP7640809B2 (ja) | 2022-01-20 | 2025-03-05 | 哈爾濱三聯薬業股▲フン▼有限公司 | ヒダントイン系化合物及びその医薬用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2468846A1 (en) | 2003-06-12 |
| US7544812B2 (en) | 2009-06-09 |
| WO2003048130A2 (en) | 2003-06-12 |
| HRP20040469A2 (en) | 2004-10-31 |
| EP1453811A2 (en) | 2004-09-08 |
| HUP0402486A2 (hu) | 2005-03-29 |
| NO20042737L (no) | 2004-08-17 |
| CN1582279A (zh) | 2005-02-16 |
| HUP0402486A3 (en) | 2007-05-02 |
| ZA200404173B (en) | 2005-08-23 |
| NZ532909A (en) | 2006-08-31 |
| PL370515A1 (en) | 2005-05-30 |
| BR0214437A (pt) | 2004-10-13 |
| MXPA04005123A (es) | 2005-02-17 |
| WO2003048130A3 (en) | 2003-11-20 |
| EA200400748A1 (ru) | 2004-12-30 |
| IL161578A0 (en) | 2004-09-27 |
| US20050020652A1 (en) | 2005-01-27 |
| AU2002356927A1 (en) | 2003-06-17 |
| EA007163B1 (ru) | 2006-08-25 |
| CO5640129A2 (es) | 2006-05-31 |
| KR20050044606A (ko) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7544812B2 (en) | Peroxisome proliferator activated receptor agonists | |
| JP4243101B2 (ja) | ペルオキシソーム増殖因子活性化受容体アルファアゴニスト | |
| DE60129712T2 (de) | Oxazolylaryloxyessigsäure derivate und ihre verwendung als ppar agonisten | |
| US20060241157A1 (en) | Heterocyclic ppar modulators | |
| AU2002228592A1 (en) | Triazole derivatives and their use as peroxisome proliferator activated receptor alpha agonists | |
| DE60128239T2 (de) | Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten | |
| US6984661B2 (en) | Urea linker derivatives for use as PPAR modulators | |
| US20090176863A1 (en) | Thiophene derivative ppar modulators | |
| DE60131001T2 (de) | Oxazolylarylpropionsäure derivate und ihre verwendung als ppar agonisten | |
| US7220880B2 (en) | Amide linker peroxisome proliferator activated receptor modulators | |
| EP1490058B1 (en) | Peroxisome proliferator activated receptor modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050929 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050929 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20080911 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090519 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20091104 |